A suspected case of Clostridium perfringens sepsis with intravascular hemolysis after transhepatic arterial chemoembolization: a case report.
Aged, 80 and over
Antibiotics, Antineoplastic
/ therapeutic use
Carcinoma, Hepatocellular
/ drug therapy
Clostridium perfringens
/ isolation & purification
Embolization, Therapeutic
/ adverse effects
Epirubicin
/ therapeutic use
Fatal Outcome
Hemolysis
Humans
Liver Neoplasms
/ drug therapy
Male
Neoplasm Recurrence, Local
/ pathology
Sepsis
/ diagnosis
Clostridium perfringens
Intravascular hemolysis
Transhepatic arterial chemoembolization
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
27 Apr 2019
27 Apr 2019
Historique:
received:
03
07
2018
accepted:
20
02
2019
entrez:
28
4
2019
pubmed:
28
4
2019
medline:
26
11
2019
Statut:
epublish
Résumé
Sepsis due to Clostridium perfringens, one of several clostridial species, is an important cause of massive intravascular hemolysis in patients with underlying malignancies. Chronic liver diseases, immunosuppression, and presence of malignancies were risk factors for Clostridium perfringens sepsis. Therefore, Clostridium perfringens sepsis should always be considered in patients presenting with liver damage after chemo-embolic therapy for hepatocellular carcinoma. This case report focuses on findings characteristic of an intravascular hemolysis due to Clostridium perfringens after transhepatic arterial chemoembolization. An 83-year-old Japanese man presented to our hospital because of a third recurrence of hepatocellular carcinoma. He had nonalcoholic steatohepatitis-related cirrhosis, and underwent radiofrequency ablation and transhepatic arterial chemoembolization therapy for hepatocellular carcinoma of S4/S8 and S2. He had a medical history of pancreatic carcinoma and underwent pylorus-preserving pancreaticoduodenectomy approximately 5 years ago. Because follow-up computed tomography showed a recurrence of the hepatocellular carcinoma, he underwent transhepatic arterial chemoembolization with a hepatic arterial infusion of 20 mg epirubicin, followed by 4 mL Lipiodol (ethiodized oil). On the sixth day after the procedure, he complained of fever and hematuria with jaundice. Laboratory findings indicated hemolysis and increased inflammatory response. Although we initiated antibiotic therapy combined with surgical debridement for infection after transhepatic arterial chemoembolization, he died within 6 hours. The autopsy showed a 4-cm local necrotic hepatic tumor. The cut surface revealed a tumor with an internal spongiform appearance, which was a pseudocystic and partially necrotic lesion. In addition, a diffuse spread of Gram-positive rods in multiple organs including the heart was histologically confirmed. The culture obtained by fluid aspiration from the hepatic abscess revealed Clostridium perfringens. Although the role of Clostridium perfringens was never established during the life of this patient, based on the clinical course and the culture from the hepatic abscess at postmortem, intravascular hemolysis secondary to Clostridium perfringens sepsis was suspected. Intravascular hemolysis secondary to Clostridium perfringens should always be considered in patients presenting with liver damage after chemo-embolic therapy for hepatocellular carcinoma. Biliary reconstruction is an especially important risk factor for infection.
Identifiants
pubmed: 31027514
doi: 10.1186/s13256-019-2023-x
pii: 10.1186/s13256-019-2023-x
pmc: PMC6486692
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
Epirubicin
3Z8479ZZ5X
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
125Références
Biochim Biophys Acta. 2003 Jun 27;1613(1-2):79-86
pubmed: 12832089
J Biochem. 2004 Nov;136(5):569-74
pubmed: 15632295
Hong Kong Med J. 2010 Aug;16(4):310-2
pubmed: 20683077
Neth J Med. 2010 Sep;68(9):343-6
pubmed: 20876913
Laeknabladid. 2012 May;98(5):289-90
pubmed: 22647407
Blood. 2013 Jul 18;122(3):310
pubmed: 24032126
Gan To Kagaku Ryoho. 2013 Nov;40(12):1795-7
pubmed: 24393925
Int J Clin Exp Pathol. 2015 Jan 01;8(1):569-77
pubmed: 25755747
World J Gastroenterol. 2015 Apr 14;21(14):4397-401
pubmed: 25892893
BMJ Case Rep. 2016 Jan 28;2016:null
pubmed: 26823354
BMJ Case Rep. 2016 Nov 25;2016:
pubmed: 27888224
Gastroenterol Hepatol. 2018 Nov;41(9):562-563
pubmed: 29455931
J Vasc Interv Radiol. 1994 Jan-Feb;5(1):167-70
pubmed: 8136598